Clinical trials: Hypoglycaemia
Diabetes, Diabetes Mellitus, Type 1
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
This study is conducted in Europe. The aim of the study is to gather information about hypoglycaemia (low blood glucose) among patients with Type 1 or Type 2 diabetes mellitus. The study is both retrospective and prospective.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01696266
- Testing
- No treatment given
- Where
- 24 sites in Argentina, Austria and 22 more
- Volunteers
- 29,304 people
- Sponsor
- Novo Nordisk A/S
Brittle Type 1 Diabetes Mellitus
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
- Trial name
- NCT05480657
- Testing
- AT-1501 IV Infusion, Isolated cadaveric islet cells
- Where
- United States
- Sponsor
- Eledon Pharmaceuticals
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03738865
- Testing
- G-Pen, Novo Glucagon
- Where
- 7 sites in United States, Austria and 1 more
- Volunteers
- 132 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 1
Evaluation of the Hypoglycaemia Notification Device Hyposafe H02
To evaluate the technical performance of the hyposafe H02 during everyday activities and during insulin-induced hypoglycaemia, in addition to safety issues associated with the implantation and use of the hyposafe H02 in subjects…
- Trial name
- NCT02925676
- Testing
- hyposafe H02
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- UNEEG Medical A/S
T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
This study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in…
- Trial name
- NCT07503028
- Testing
- CRG002
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Celregen Therapeutics
Type 1 Diabetes, Hypoglycemia
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
The purpose of this study is to determine whether ZT-01 increases the glucagon response to hypoglycemia in type 1 diabetes (T1D).
- Trial name
- NCT05007977
- Testing
- ZT-01 low dose, ZT-01 high dose
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Zucara Therapeutics Inc.
Congenital Hyperinsulinism
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to…
- Trial name
- NCT04172441
- Testing
- dasiglucagon
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypoglycemia
Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
BIOD-961 is a dry powder formulation of glucagon intended for use in a device that mixes (reconstitutes) the powder with liquid to make it easier for users to treat patients with severe hypoglycemia.
- Trial name
- NCT02403648
- Testing
- BIOD-961, Lilly Glucagon, Novo Glucagon
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Biodel
Hypoglycemia
Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia
The purpose of this study is to determine whether glucagon administered by microneedle patch is comparable to glucagon administered by injection pen in the treatment of insulin-induced hypoglycemia.
- Trial name
- NCT02459938
- Testing
- Glucagon (ZP-Glucagon), Glucagon (GlucaGen)
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Zosano Pharma Corporation
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia
- Trial name
- Pilot'Ex (NCT05221359)
- Testing
- ExOlin®, Insulin aspart
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Defymed
Hypoglycemia, Diabetes Mellitus, Type 1
A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion
A single center pilot study assessing the Vigilant Diabetes Management Companion for the prevention of recurrent nocturnal hypoglycemia in type I diabetes patients.
- Trial name
- NCT02906891
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Diabetes Mellitus, Type 1
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use…
- Trial name
- RECORD-IQ (NCT07211126)
- Testing
- t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
- Where
- 25 sites in France
- Volunteers
- 350 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
This study will be conducted in a Clinical Research Center (CRC) setting and recruiting type 1 diabetes that are currently using an insulin pump.
- Trial name
- NCT01919385
- Testing
- Predictive Low Glucose Minimizer
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Type 1 Diabetes Mellitus
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes.
- Trial name
- NCT06272695
- Testing
- Volagidemab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- REMD Biotherapeutics, Inc.
Diabetes Mellitus Type 1
A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose.
- Trial name
- SUGR (NCT06651515)
- Testing
- Allogeneic Pancreatic Endocrine Cell Clusters
- Where
- 2 sites in United States
- Sponsor
- Seraxis
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Postbariatric Hypoglycemia
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts.
- Trial name
- NCT06036784
- Testing
- MBX 1416 (Part A), MBX 1416 (Part B), MBX 1416 (Part C)
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- MBX Biosciences
Drug-specific Antibodies, Diabetes Mellitus
Evaluate the Immunogenicity of a Novel Glucagon Formulation
This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards to the potential development of treatment-emergent anti-glucagon antibodies.
- Trial name
- NCT01959334
- Testing
- Nasal Glucagon (NG), Glucagon IM
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia
Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)
The primary objective of this study is to ascertain the pharmacokinetics (PK) and pharmacodynamics (PD) bioequivalence of a subcutaneous (SC) injection of 1 mg (1 IU) of Glucagon (Fresenius Kabi USA) in comparison to the…
- Trial name
- NCT02086227
- Testing
- Glucagon for Injection (Fresenius Kabi USA), Glucagon for Injection (Bedford Laboratories)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi USA, LLC